Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 47.0%

Neg 47% Neu 0% Pos 0%

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.